Brinker Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Brinker Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$2.23M	Buy	20,213 +484	+2%	+$53.5K	0.07%	269
2020 Q1	$1.97M	Sell	19,729 -853	-4%	-$110K	0.08%	241
2019 Q4	$3.07M	Sell	20,582 -375	-2%	-$51K	0.1%	208
2019 Q3	$2.69M	Buy	20,957 +4,034	+24%	+$541K	0.09%	216
2019 Q2	$2.41M	Buy	16,923 +931	+6%	+$125K	0.09%	223
2019 Q1	$2.29M	Buy	15,992 +4,365	+38%	+$569K	0.09%	233
2018 Q4	$1.44M	Buy	11,627 +518	+5%	+$76.8K	0.06%	301
2018 Q3	$1.87M	Buy	11,109 +879	+9%	+$151K	0.07%	307
2018 Q2	$1.76M	Buy	10,230 +5,963	+140%	+$975K	0.07%	304
2018 Q1	$644K	Buy	4,267 +1,803	+73%	+$264K	0.03%	625
2017 Q4	$332K	Buy	+2,464	New	+$342K	0.01%	813

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Brinker Capital's JAZZ Position: Q2 2020 in Review

Brinker Capital increased its Jazz Pharmaceuticals (JAZZ) stake by 2.5% in Q2 2020, buying an estimated $53.5K and bringing the position to 20,213 shares worth $2.23M. The position accounts for 0.07% of the portfolio, ranked #269.

Brinker Capital first reported a position in JAZZ in Q4 2017 and has held it in 11 quarters since. The position peaked at $3.07M in Q4 2019. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

Brinker Capital held 20,213 shares of Jazz Pharmaceuticals worth $2.23M as of Q2 2020.
Brinker Capital bought 484 Jazz Pharmaceuticals shares in Q2 2020, an estimated $53.5K.
Jazz Pharmaceuticals made up 0.07% of Brinker Capital's portfolio in Q2 2020, its #269 holding.
Brinker Capital first reported a position in Jazz Pharmaceuticals in Q4 2017 and has held it in 11 quarters since.
Brinker Capital's Jazz Pharmaceuticals position peaked at $3.07M in Q4 2019.
384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.